Quest Diagnostics Launches 88-Compound Novel Psychoactive Substance Test Panel
The new panel from Quest tests for 88 compounds, and covers a broad array of drug classes, and other illicit additives.
Read MorePosted by Andy Lundin | Dec 19, 2023 | Urinalysis & Toxicology |
The new panel from Quest tests for 88 compounds, and covers a broad array of drug classes, and other illicit additives.
Read MorePosted by Chris Wolski | Dec 6, 2023 | Calibrators |
Kits are available from Verichem Laboratories for the calibration verification testing of both urine and serum magnesium assays.
Read MorePosted by Andy Lundin | Dec 1, 2023 | Urinalysis & Toxicology |
This product design aims to transform workflows, expediting results for labs tasked to provide care for victims of drug-facilitated crimes.
Read MorePosted by Chris Wolski | Nov 23, 2023 | Company News |
BD has announced that Ronald Silverman, MD, FACS, has been named executive VP and chief medical officer of BD, effective Dec. 4, 2023.
Read MorePosted by Chris Wolski | Nov 16, 2023 | Diagnostic Technologies |
Consolidation, legislation, new testing types, and a shift to more consumer-driven testing are some clinical laboratory predictions for 2024.
Read More